Page last updated: 2024-12-10
opc 8490
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
OPC 8490: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3035953 |
SCHEMBL ID | 8212456 |
MeSH ID | M0170237 |
Synonyms (10)
Synonym |
---|
opc 8490 |
piperazine, 1-(4-oxo-4-phenylbutyl)-4-((1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)carbonyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
opc-8490 |
123941-50-4 |
3,4-dihydro-6-(4-(4-oxo-4-phenylbutyl)-1-piperazinylcarbonyl)-2(1h)-quinolinone |
SCHEMBL8212456 |
DTXSID40154152 |
2-hydroxypropane-1,2,3-tricarboxylic acid;6-[4-(4-oxo-4-phenylbutyl)piperazine-1-carbonyl]-3,4-dihydro-1h-quinolin-2-one |
2(1h)-quinolinone, 3,4-dihydro-6-[[4-(4-oxo-4-phenylbutyl)-1-piperazinyl]carbonyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
AKOS040753378 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 5 (83.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.05
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.05) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |